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Introduction: Natalizumab blocks α4-integrins and is a prototypic agent for a series of anti-inflammatory drugs that
impair trafficking of immune cells into the CNS. However, modulation of the access of immune cells to the CNS is
associated with impaired immune surveillance and detrimental viral infections of the CNS. Here, we explored the
potency of cellular immune responses within the CNS to protect against viral encephalitis in mice with T cell
conditional disruption of VLA-4 integrin (α4β1) expression.
Results: While VLA-4 expression in virus specific Th1 cells is non-redundant for their ability to access the CNS,
α4-integrin deficient Th17 cells enter the CNS compartment and generate an inflammatory milieu upon intrathecal
vaccinia virus (VV) infection. However, in contrast to Th1 cells that can adopt direct cytotoxic properties, Th17 cells
fail to clear the virus due to insufficient Eomes induced perforin-1 expression.
Conclusion: The quality of the intrathecal cellular antiviral response under conditions of impaired VLA-4 function
jeopardizes host protection. Our functional in vivo data extend our mechanistic understanding of anti-viral immunity
in the CNS and help to estimate the risk potential of upcoming therapeutic agents that target the trafficking of
immune cells into distinct anatomical compartments.Introduction
Autoimmune inflammation of the CNS in multiple scler-
osis (MS) and its animal model, experimental autoimmune
encephalomyelitis (EAE), is mediated by antigen specific
Th1 and Th17 cells [1]. For many years integrin targeted
blocking of T helper cell trafficking into the CNS has
appeared to be an attractive approach to treat immuno-
pathology in MS [2]. In particular, monoclonal anti-
bodies (natalizumab) to the α4 subunit of the integrin
VLA-4 (α4β1 heterodimer) were successfully used to
prevent the influx of immune cells into the CNS and to
treat CNS autoimmunity [3]. However, in experimental
models it has been shown that distinct encephalitogenic
T cell subsets vary in their equipment with VLA-4 [4].* Correspondence: korn@lrz.tum.de
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article, unless otherwise stated.While Th1 cells maintain high amounts of VLA-4 expres-
sion, Th17 cells are low in VLA-4. As a consequence,
blockade of VLA-4 is more efficient in preventing the
recruitment of Th1 cells than of Th17 cells into the
CNS parenchyma.
Although considered as an “immune privileged” organ,
the CNS is still patrolled by T cells as a means of immune
surveillance [5]. The contribution of CD4+ vs CD8+
effector memory T cells in the migratory and resident
pools of lymphocytes specific to a given pathogen has
been investigated in skin infection but is unclear in the
CNS [6]. In the treatment of organ specific autoimmunity
and chronic inflammation, efforts are increasing to market
compounds that either inhibit immune cell trafficking
[7-10] or cytokine networks that affect distinct T helper
cell subsets in a differential manner (anti-IL-23p19, anti-
IL-17A [11,12], anti-GM-CSF (NCT01517282), anti-IL-6R
[13]). However, preclinical models to investigate niche
specific immune surveillance and host defense in the CNS
are rare. Indeed, efalizumab, a blocking antibody to theentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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because of viral meningitis and cases of JC virus induced
progressive multifocal leukencephalopathy (PML) [14].
Here, we established a CNS specific viral infection
model that allowed us to analyze the contribution of dis-
tinct T helper cell subsets to host protection. We chose
vaccinia virus (VV) infection where the importance of
virus specific T helper cell responses has been analyzed
previously [15,16]. Vaccinated mice were found to be
protected from intrathecal (i.th.) infection with VV due
to cellular immunity. In the absence of CD8+ T cells,
Th1 like cells were sufficient to protect mice from intra-
thecal VV infection. Access of Th1 cells into the infected
CNS compartment was dependent on VLA-4 expression.
Although virus specific Th17 cells were able to migrate
into the CNS in the absence of VLA-4, CNS recruited
and infected macrophages were not cleared by Th17
cells since Th17 cells – in contrast to Th1 cells – were
deficient in perforin-1 expression. These data highlight
a dominant role of Th1 cells in antiviral tissue-specific
immunity. Our data further suggest that as in auto-
immune inflammation of the CNS, virus specific Th1
cells are dependent on VLA-4 to enter into the CNS
and virus infection does not overcome the requirement
for Th1 cells to express VLA-4. Thus, integrin targeted
therapeutic interventions in autoimmunity and chronic
inflammation need to be refined in order to not
jeopardize organ specific immune surveillance and
host protection.
Materials and methods
Animals, immunization, and infection
Foxp3gfp.KI mice [17,18] and Itga4flox/flox mice [19] have
been described previously. CD4 Cre mice, Ifng-/- mice,
Rag1-/- mice, Prf1-/- mice, and wild type C57BL/6 mice were
obtained from Jackson Laboratories. CD45.1+ OT-II mice
were kindly provided by DH Busch (Institute for Medical
Microbiology, Immunology, and Hygiene, Technische
Universität München). All mouse strains were on pure
C57BL/6 background.
Mice were immunized by subcutaneous injection of
100 μl of an emulsion of 1 × 108 IU MVA or PBS in
complete Freund’s adjuvant (CFA). For in vivo blockade
of IFN-γ, mice were treated with every other day i.p. in-
jections of a neutralizing antibody to IFN-γ (R4-6A2,
BioXCell, West Lebanon, USA; 200 μg) or isotype control
starting on day 9 after immunization. In a similar regimen,
blocking antibodies to integrin α4 (PS/2, BioXCell, West
Lebanon, USA; 200 μg), depleting antibodies to CD8
(YTS169.4, BioXcell; 200 μg) or CD4 (GK1.5, BioXcell;
200 μg) were administered every other day from day 9 or
day 10 after immunization, respectively.
Intrathecal infection was performed as previously
described [20]. In brief, VV was inoculated into thecisterna magna of mice in deep anaesthesia by means of
transcutaneous suboccipital puncture. Clinical signs of
disease as well as weight loss in percent of initial weight
(means + SEM) were monitored daily.
For adoptive transfer experiments, naïve T cells were
isolated by magnetic sorting (CD4+CD62L+; T cell isola-
tion kit II, mouse; Miltenyi Biotec, Germany) from
CD45.1+ OT-II mice and differentiated in vitro into Th1
or Th17 cells. The differentiation status was checked on
day 4 by intracellular cytokine staining and 2 × 106 cyto-
kine positive T cells were injected i.v. into Rag1-/- recipi-
ent mice, which had been infected with VV-Ova one day
prior to T cell transfer.
Animals were kept in a specific pathogen-free facility
at the Technische Universität München. All experimen-
tal protocols were approved by the standing committee
for experimentation with laboratory animals of the
Bavarian state authorities (“Governmental Department
of Upper Bavaria, Approved animal experimental pro-
posals No 55.2-1-54-2531-88-08 and No 55.2.1-54-2532-
29-13 according to §8.1, German law for experimentation
with laboratory animals”) and carried out in accordance
with the corresponding guidelines.
Virus strains
Replication competent VV Western Reserve strain (VV)
was provided by B Moss (National Institutes of Health,
Bethesda, MD). Recombinant viruses encoding en-
hanced green fluorescent protein (VV eGFP) or full-
length ovalbumin (VV-Ova) based on the Western
Reserve strain were provided by JW Jewdell and JR Ben-
nink (National Institutes of Health, Bethesda, MD). VV
and replication deficient Modified Vaccinia Virus
Ankara strain (MVA, cloned isolate IInew) used in this
study were propagated and titered according to stand-
ard methodology [21].
T cell differentiation
Naïve T cells (CD4+CD62LhighCD25-) were isolated from
lymph nodes and spleen by magnetic sorting (T cell iso-
lation kit II, mouse; Miltenyi Biotec, Germany). Purity
was in general higher than 95% as controlled by FACS
staining. Naïve T cells were stimulated for 3 to 5 days
with plate-bound antibody to CD3 (145-2C11, 4 μg/ml)
and antibody to CD28 (PV-1, 2 μg/ml). Recombinant
cytokines were added to the differentiation cultures as
indicated: human TGF-β1 (2 ng/ml) and mouse IL-6
(50 ng/ml) for Th17, mouse IL-12 (10 ng/ml) and anti-
IL-4 (10 μg/ml) for Th1, all R&D Systems.
Preparation of splenic and CNS mononuclear cells and
antibody staining
Mononuclear cells were isolated from either spleen or
CNS at the peak of disease (d4-d5 after intrathecal
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tricle with cold PBS, the brain including cerebellum was
dissected and the spinal cord flushed out with PBS by
hydrostatic pressure. CNS tissue was digested with colla-
genase D (2.5 mg/ml, Roche Diagnostics, Indianapolis
IN) and DNAseI (1 mg/ml, Sigma, Saint Louis, MO) at
37°C for 45 min. Mononuclear cells were isolated by
passing the tissue through a cell strainer (70 μm) and
percoll gradient (37% over 70%) centrifugation. Mono-
nuclear cells were removed from the interphase, washed
and resuspended in culture medium for further analysis.
For isolation of mononuclear cells from spleen, spleens
were mashed through a cell strainer (70 μm) and red
blood cells were removed using BD Pharm Lyse (BD
Biosciences). Surface staining of T cells was carried out
with antibodies to CD3 (14-2C11), CD4 (RM4-5), CD8
(53-6.7), CD11b (M1/70), CD25 (PC61 or 7D4), CD44
(IM7), CD45 (30-F11) and Nk1.1 (PK136). All antibodies
were purchased from BD Biosciences. Fluorescence-
labeled MHC class I H-2Kb/B8R20-27 (TSYKFESV) mul-
timers were provided by DH Busch.
Intracellular cytokine staining
Cells were stimulated in culture medium containing
phorbol 12-myristate 13-acetate (PMA, 50 ng/ml, Sigma),
ionomycin (1 μg/ml, Sigma), and monensin (GolgiStop
1 μl/ml, BD Biosciences) at 37°C and 10% CO2 for
4 hours. After staining of surface markers, cells were
fixed and permeabilized (Cytofix/Cytoperm and Perm/
Wash buffer, BD Biosciences) followed by staining with
monoclonal antibodies to mouse IL-2, IL-17, or IFN-γ
(BD Biosciences) and flow cytometric analysis (CYAN,
Beckmann/Coulter).
Histologic analysis
For detection of VV-infected cells or macrophages, para-
formaldehyde (PFA) (4%) fixed and paraffin embedded
CNS tissue sections were incubated with Bond Primary
Antibody Diluent (Leica) containing either polyclonal
rabbit anti-VV serum (1:1000; Quartett Immunodiagnos-
tika & Vertriebs-GmbH, Berlin) or monoclonal anti-
bodies against Mac-3 (1:750; M3/84) purchased from BD
Pharmingen. IHC staining was performed on an auto-
mated Leica BOND-MAX instrument using Bond Polymer
Refine Detection Solution for DAB. For detection of GFAP,
PFA-fixed and paraffin-embedded CNS sections were
incubated with Dako polyclonal rabbit anti-GFAP anti-
bodies (Z0034; 1:13000) in Ventana buffer and staining
was performed on a Ventana NexES IHC Slide Stainer
using iVIEW DAB Detection Kit (Ventana). Images
were taken using the Leica SCN400 slide scanner ana-
lysis software or were acquired on an Olympus BX53
Microscope (DP72 camera) using the cellSens 1.8
digital imaging software (Olympus).Quantitative PCR analysis
For quantitative PCR, RNA was extracted from magnetic
bead-purified or flow cytometry-sorted cells ex vivo or
after in vitro differentiation using RNeasy columns (Qiagen,
Valencia, CA). Complementary DNA was transcribed as
recommended (Applied Biosystems, Foster City, CA) and
used as template for quantitative PCR. Primer plus probe
mixtures were obtained from Applied Biosystems. The
Taqman analysis was performed on a StepOne system
from Applied Biosystems. The gene expression was
normalized to the expression of β-actin.
Western blotting
T cells were lysed and denatured using RiPA buffer
(Sigma-Aldrich). The protein lysates were separated by
SDS-PAGE in 4–12% NuPAGE Bis-Tris Mini gels and
transferred to nitrocellulose membranes (Invitrogen).
After blocking with 5% low-fat dry milk in TBS-T,
membranes were incubated with primary antibodies to
Prf-1 (ab7203, Abcam) and β-actin (Abcam) in blocking
solution overnight at 4°C. Primary antibody binding
was detected with HRP-conjugated secondary antibodies
(Dianova). The signal was visualized by enhanced chemi-
luminescence (Novex ECL, Invitrogen).
Antigen specific proliferative and cytokine responses
For CD154 (CD40L) staining, spleens from MVA immu-
nized CD4 Cre- × Itga4flox/flox or CD4 Cre+ × Itga4flox/flox
mice were dissected on day 10 after immunization. Sin-
gle cell suspensions were prepared and cells were seeded
on a 12 well flat-bottom plate at a density of 2 × 106
cells/well. Single cells were restimulated with a mixture
of I-Ab-restricted VV peptides (A33R, B2R, B5R, L4R;
30 μg/ml each) for 6 hours in the presence of brefeldin
A (5 μg/ml) during the last 3 hours of incubation followed
by surface and intracellular staining for CD40L (CD154
(MR1), eBioscience) and cytokines as indicated. A33R116-130
(YQLFSDAKANCTAES), B2R46-60 (VKDKYMWCYSQ
VNKR), B5R46-60 (FTCDQGYHSSDPNAV) and L4R176-190
(ISKYAGINILNVYSP) were obtained from Biosyntan,
Berlin.
Retroviral transduction of T cells
pMIG Eomes (GFP) and control pMIG (GFP) retroviral
constructs were a kind gift from SL Reiner (University of
Pennsylvania, Philadelphia, PA) and FJ Quintana (Harvard
Medical School, Boston, MA). Phoenix-Eco cells (PMID:
18432682, a kind gift of H-M Jaeck, Erlangen) were transi-
ently transfected with plasmids by calcium phosphate pre-
cipitation in the presence of 25 μM chloroquine (Sigma
Aldrich). Retroviral supernatants were collected two days
post transfection. T cells were transduced 24 hours post
polyclonal in vitro activation of naïve sorted CD4+ T cells
with TGF-β and IL-6 (Th17). Retroviral supernatant and
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pre-committed Th17 cells and a spin transduction was
performed (2000 rpm, RT, 1 hour). Cells were further
cultured for 3 days in Th17 polarizing conditions before
GFP expressing cells were purified by FACS sorting and
subjected to quantitative PCR analysis.
Plaque assay
CNS tissue was digested as described and single cell sus-
pensions were obtained by passing digested CNS tissue
through a 70-μm nylon filter. Pelleted cells were sub-
jected to three freeze-thaw cycles (-80°C and 37°C) and
sonicated three times for 1 min. Serial dilutions in
RPMI-1640 medium containing 10% FCS were added in
duplicates to 90% confluent RK-13 cells seeded in 6-well
plates and incubated for 24 hours at 37°C. Plaques were
counted after crystal violet staining.
Neutralization assay
Mouse serum samples were collected at day 10 post
immunization (MVA/CFA or PBS/CFA). All serum sam-
ples were heat-inactivated at 56°C for 30 min prior to
testing. Serum dilutions were incubated with 10,000
PFU of sucrose gradient purified VV eGFP for 1 hour at
37°C and 5% CO2 in a 96-well plate. RK-13 cells were
added and infection (MOI = 0.1) was carried out over
night at 37°C and 5% CO2. Cells were harvested, washed
and fixed in 1% paraformaldehyde. Percentage of
VV-infected cells was determined by measuring eGFP ex-
pression in flow cytometric analyses (CYAN, Beckmann/
Coulter). The percentage of virus neutralization was
defined as (1-[percentage of GFP-expressing cells]/
[percentage of GFP-expressing cells in controls with-
out serum]) × 100.
Statistical analysis
Statistical evaluations of cell frequency measurements
and gene expression levels were performed with the
unpaired Student’s t test. Two-tailed p values < 0.05
were considered significant. Weight scores are given as
means ± SEM. Multiple comparisons were performed
by two-way-ANOVA and Bonferroni post-testing.
Results
Intrathecal vaccinia virus (VV) infection causes
lethal encephalitis
To establish a model of viral encephalitis, female C57BL/6
mice were injected intrathecally with VV by suboccipital
puncture of the cisterna magna. By titrating the dose of
the inoculum, the half lethal dose (LD50) was determined
to be approximately 500 plaque forming units (PFU)
(Figure 1A). In systemic infection, VV is known to pref-
erentially replicate in the ovaries upon hematogenous
dissemination. We therefore measured viral loads inCNS and ovaries of mice injected i.th. with 1.000 PFUs
of VV. While high titers of VV were measured in the
CNS, virus was not detected in the ovaries of intra-
thecally infected mice (Figure 1B) indicating that intra-
thecal injection of VV led to a compartmentalized
infection within the CNS without systemic dissemin-
ation. Within the CNS compartment, VV antigen was
detected in ventricular lining cells and plexus epithe-
lium cells as well as in astrocytes of the glia limitans.
Some innate immune cells of monocytic origin that
were recruited to the infected CNS compartment were
also positive for VV antigen (Figure 1C).
In order to determine immune cell targets of VV
within the CNS, we infected wild type mice with recom-
binant VV expressing enhanced green fluorescent pro-
tein (VV eGFP). When analyzing eGFP expression in
distinct cell populations of the CNS on day 4 after infec-
tion, we found a sizable fraction of eGFP expressing cells
only within the CD11bhighCD45high macrophage com-
partment (Figure 2). This is in line with a recent study
which identified infiltrating CD11b+CD45+ inflammatory
monocytes as the predominant VV infected leukocyte
population during VV skin infection [22]. Microglial
cells (CD11b+CD45low), T cells and B cells did not show
eGFP expression. In addition, we were unable to detect
eGFP expressing cells in the spleens of intrathecally
injected mice, further demonstrating that VV infection
was restricted to the CNS compartment. Importantly,
infected CD11b+CD45high macrophages expressed MHC
class II (Figure 2B). Thus, phagocytic cells were re-
cruited from the systemic compartment in response to
i.th. VV infection and became targets of virus replication
but were unable to control the infection (see Figure 1A).
Immunization with modified vaccinia virus (MVA) protects
against VV encephalitis
As macrophages became infected during VV encephalitis
but failed to eliminate the virus, we hypothesized that
adaptive cellular immune responses were required for
virus control. In order to investigate the contribution of
antigen specific effector T helper cells to host defense
against i.th. VV infection, we immunized wild type mice
with a replication deficient strain of VV (MVA) emulsi-
fied in complete Freund’s adjuvant (CFA) 10 days prior
to i.th. challenge with VV. CFA induces both Th1 and
Th17 responses. Here, we were interested in investigat-
ing the role of these T helper cell subsets in the trade-off
between host protection and immunopathology during
infectious encephalitis. While sham-immunized mice
died at day 6 after infection and largely failed to recruit
either CD4+ T helper cells or VV-specific CTLs into the
CNS compartment (Figure 3A,B), MVA immunized
animals harbored both antigen specific CTLs and CD4+ T
cells in the CNS and recovered from VV encephalitis
Figure 1 Intrathecal infection with VV causes lethal encephalitis. (A) C57BL/6 wild type mice were injected intrathecally by suboccipital
puncture of the cisterna magna with various doses of VV. Percentage of surviving mice are depicted in Kaplan-Meier curves (n = 5 per group).
(B) Virus loads in CNS and ovaries of wild type mice infected intrathecally with VV were measured on day 5 after infection (Student’s t test,
n ≥ 5). (C) Wild type mice injected with VV were subjected to histologic analyses on day 5 after infection. Unless otherwise indicated, scale
bars represent 200 μm in the low magnification and 20 μm in the higher magnification photomicrographs.
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largely produced IFN-γ, the intrathecal CD4+ effector T cell
compartment comprised IFN-γ producers, IL-17 producers,
and IFN-γ/IL-17 double producers (Figure 3C). In sum-
mary, protective immunity against intrathecal VV infec-
tion was associated with the mobilization of both CTLs
and CD4+ effector T helper cells to the CNS.
Antibody mediated blockade of α4-integrins leads to
relative enrichment of Th17 cells in the CNS
We next wished to dissect the specific contribution of
different T cell subsets to the protective effects of
vaccination. Here, we took advantage of the differential
integrin requirement for the recruitment of Th1 cells vsTh17 cells into the CNS compartment. In the EAE
model, Th1 cells depend on α4-integrins in order to
enter into the CNS during autoimmune inflammation.
In contrast, Th17 cells are able to access the CNS com-
partment independently of α4-integrins using an LFA-1
dependent mechanism [4]. Here, we treated our MVA
immunized mice with blocking antibodies to integrin α4
(PS/2) prior to i.th. VV challenge (Figure 4A). Notably,
MVA immune mice survived i.th. VV infection in spite
of integrin α4 blockade (Figure 4A). As expected, we
found a relative abundance of IL-17 producing T cells as
compared with IFN-γ positive T helper cells (Figure 4B).
This finding supported the idea that – similar to T
cell recruitment in autoimmune inflammation of the


















































































Figure 2 MHC class II positive macrophages are targets of VV infection in the CNS. Wild type mice were infected intrathecally with 1.000
PFUs of VV (eGFP), a replication competent recombinant VV expressing enhanced green fluorescent protein (eGFP) in infected cells. On day 4
after infection, mice were sacrificed, and spleen and CNS mononuclear cells were isolated and analyzed by flow cytometry. In the live cell gate,
the following populations were defined based on their expression of CD11b and CD45: (A) spleen (SPL), left panel: (1) CD11blowCD45high
lymphocytes, (2) CD11bintCD45high dendritic cells, (3) CD11bhighCD45high macrophages. (A) CNS, right panel: (1) CD11blowCD45high lymphocytes, (2)
CD11bintCD45int microglia, (3) CD11bhighCD45high macrophages. (B) These populations were analyzed as to their expression of eGFP and MHC class II
by flow cytometry. Numbers indicate percentages of positive cells in each quadrant or gate (representative out of 3 independent experiments).
Rothhammer et al. Acta Neuropathologica Communications 2014, 2:27 Page 6 of 16
http://www.actaneurocomms.org/content/2/1/27
Rothhammer et al. Acta Neuropathologica Communications 2014, 2:27 Page 7 of 16
http://www.actaneurocomms.org/content/2/1/27CNS – Th1 cells and Th17 cells exhibited distinct
integrin requirements for their entry into CNS in
the context of a local virus infection. Interestingly,
while the absolute number of CD4+ T cells was reduced in
the CNS, which was largely due to the reduction of IFN-γ
producing CD4+ effector T cells, the number of CTLs
recruited to the CNS compartment was not significantly
reduced in anti-integrin α4 treated mice (Figure 4C).
Thus, integrin α4 mediated mechanisms appeared to be
redundant for the recruitment of effector CD8+ T cells
into the infected CNS.
Th17 cells fail to clear cerebral VV infection
Similar to the murine system, neutralization of α4-
integrins by natalizumab in humans mainly blocks CD4+ T
cells from entering into the CNS compartment but
spares CD8+ T cells [23,24]. Yet, intracerebral reconsti-
tution of CD4+ effector T helper cell responses has
been proposed to be necessary for efficient clearance
of various viruses from the CNS including JC virus
[25]. We wanted to dissect the essential features of an
intracerebral T helper cell response that would be able
to control viral infection. Thus, we combined a system
of T cell conditional ablation of α4-integrin expression
(CD4 Cre+ x Itga4flox/flox mice, α4 CKO mice) with
antibody mediated depletion of CD8+ T cells in order
to investigate the differential contribution of Th1 cells
vs Th17 cells to host protection in CNS infection in
the absence of CTLs. To exclude possible alterations
in priming of antigen specific T helper cell responses
in the peripheral immune compartment of α4 CKO
mice, we compared the fractions of antigen specific T
cells on day 10 after subcutaneous immunization with
MVA/CFA in the spleens of CD4 Cre- x Itga4flox/flox
(wild type control) versus CD4 Cre+ x Itga4flox/flox (α4
CKO) mice (Additional file 1: Figure S1). Upon ex vivo
restimulation with I-Ab restricted VV epitopes, the
fractions of antigen specific (CD40L+) CD4+ T cells
and their cytokine profile were similar in wild type vs
α4 CKO mice. Moreover, the anti-VV neutralizing serum
response was equally effective in both groups on day 10
after immunization (Additional file 1: Figure S1). Thus,
sensitization for adaptive cellular immune responses
against VV in draining lymph nodes and spleen was not
impaired by the lack of α4-integrins on T cells.
Next, we challenged MVA immune and CD8+ depleted
wild type and α4 CKO mice with i.th. VV. In contrast to
control littermates, α4 CKO mice rapidly lost weight
and succumbed to infection (Figure 5A). Even in the
complete absence of CD8+ T cells (Figure 5B), CD4+ ef-
fector T helper cells were protective in wild type mice
but failed to control virus replication in the CNS of α4
CKO mice (Figure 5C). Recapitulating our observations
with anti-α4 integrin (PS/2) administration, α4-integrindeficient T helper cells re-isolated from the CNS of
VV challenged mice exhibited a Th17 like phenotype
while the number of Th1 like cells was significantly
reduced in α4 CKO animals as compared with controls
(Figure 5D, E). Consistent with their cytokine produc-
tion upon ex vivo stimulation, CNS derived α4-integrin
deficient T helper cells expressed higher amounts of
Th17 signature markers such as Rorc, Il17, Il22, Il6,
Ccr6, or Il1r1 whereas Th1 associated genes like Cxcr3,
Ccr5, or Ccr2 prevailed in wild type T helper cells
(Figure 5F). In conclusion, while Th1 cells appeared to
be sufficient to provide host protection in intrathecal
VV infection, Th17 cells failed to control cerebral virus
replication in the absence of CD8+ T cells resulting in
lethal encephalitis.
To corroborate that Th1 immunity was sufficient to
improve the outcome of intrathecal viral infection, we
established a model of adoptively transferred host pro-
tection using OT-II T cells, which carry a transgenic T
cell receptor specific to ovalbumin, in combination with
a recombinant VV expressing ovalbumin in infected cells
(VV-Ova). Naive OT-II cells were differentiated in vitro
into Th1 cells or Th17 cells followed by transfer into
Rag1-/- mice, which had been infected intrathecally with
VV-Ova one day prior to adoptive transfer (Figure 6).
While non-transferred Rag1 deficient recipients and recip-
ients of Th17 cells rapidly died, Th1 recipients survived
significantly longer than their counterparts (Figure 6A).
Despite a significant difference in clinical outcome, equal
amounts of transferred Th1 cells and Th17 cells were re-
isolated from the CNS of infected mice (Figure 6B). Thus,
on a per cell basis, antigen specific Th1 cells appeared to
be more potent in alleviating i.th. virus infection than
antigen specific Th17 cells.
Th17 cells fail to clear i.th. VV infection due to lack of
perforin-1 expression
It was possible that the reduced capacity of Th17 cells to
provide host protection in intrathecal VV infection was
simply due to reduced availability of IFN-γ within the
CNS compartment. In order to test this possibility, we
neutralized IFN-γ by monoclonal antibodies in MVA
immune and CD8+ T cell depleted wild type mice
(Additional file 2: Figure S2). In this purely T helper cell
dependent scenario, VV specific Th1 and Th17 cells
were generated and had access to the VV challenged
CNS. Notably, the mice recovered from VV encephalitis
despite ablation of IFN-γ. Efficiency of IFN-γ blockade
was documented by reduced levels of MHC class II
expression on microglial cells in the CNS compartment
(Additional file 2: Figure S2). These data suggested that
IFN-γ was redundant as an effector molecule in the
clearance of intrathecal VV infection and refuted the






















































































































Figure 3 Immunization with modified VV Ankara (MVA) confers protective immunity against viral encephalitis. Wild type mice were
immunized subcutaneously with a replication deficient strain of VV (Modified Vaccinia Virus Ankara, MVA) or PBS emulsified in complete Freund’s
Adjuvant (CFA). On day 10 after immunization, mice were challenged intrathecally with VV, and weight courses were monitored daily as percentage of
initial body weight (A, n = 5 mice per group). On day 4 after infection, CNS infiltrating mononuclear cells were isolated. (B) Absolute numbers of CNS
infiltrating CD4+ and CD8+ T cells. Horizontal bars indicate means (Student’s t test; n≥ 5 per group). (C) CNS derived T cells were analyzed as to their
specificity to the VV MHC class I restricted epitope B8R by multimer staining and to their IL-17 and IFN-γ cytokine status by intracellular
cytokine staining in the CD3+CD8+ CTL and CD3+CD4+ T helper cell compartment, respectively. Numbers indicate percentages of cells in
the depicted gates or quadrants; representative out of more than 5 independent experiments).
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VV infection.
In order to define potential molecular mechanisms of
T helper cell mediated host protection in intracerebral
viral infection, we screened the expression profile of
highly purified CD4+ effector T cells isolated from the
CNS of VV challenged wild type vs α4 CKO mice for
molecules directly involved in virus defense (Figure 7A).
CD4+ effector T cells expressed Tnf, Grzmb, and Fasl
irrespective of whether they were derived from the Th1
biased inflammatory infiltrate of wild type mice or from
the Th17 biased inflammatory milieu of α4 CKO mice.
In contrast, the expression of perforin-1 (Prf1) was
markedly reduced in α4-integrin deficient as compared
with wild type T helper cells. In order to correlate lack
of Prf1 expression with the Th17 transcriptional pro-
gram, we purified CD3+CD4+CD44-Foxp3- naïve T cells
from Foxp3gfp.KI mice and stimulated them without
exogenous cytokines (Th0) or differentiated them into
Th1 cells or Th17 cells (Figure 7B). Consistent with our
in vivo data, we found a significant reduction in Prf1
mRNA and protein in Th17 as compared with Th1 and
Th0 cells. Notably, protein expression of Prf1 was only
seen at late time points (Figure 7B). Since expression of
Prf1 has been reported to depend on the expression of
the transcription factor eomesodermin (Eomes) [26], we
measured RNA levels of Eomes in CD4+ T cells isolated
from brains of VV infected wild type and α4 CKO mice.
Consistent with the low expression of Prf1 in Th17 cells,
Eomes mRNA levels were reduced in CD4+ T cells iso-
lated from α4 CKO mice as compared with wild type
controls (Figure 7C). To formally validate whether
reduced Eomes expression in Th17 cells accounted for
diminished Prf1 expression as compared with Th0 and
Th1 cells, we polarized Th17 cells in vitro and overex-
pressed Eomes by retroviral transduction (Figure 7D).
FACS sorted transduced (GFP+) Th17 cells expressed
abundant levels of Eomes as compared with control
vector proving effective transduction; concomitantly, Prf1
RNA was significantly increased in Eomes transduced
Th17 cells. These data suggested that the failure of Th17
cells to express Prf1 was due to reduced Eomes expression.
In order to explore the importance of CD4+ T cell de-
rived Prf1 for successful host defense in CNS virus infec-
tion in vivo, we immunized Prf1 deficient mice (Prf1-/-)
with MVA/CFA and established viral encephalitis in
CD8+ T cell depleted animals by intrathecal infection
with VV (Figure 8). While wild type mice recovered
from i.th. VV challenge, Prf1 deficient mice succumbed
to viral encephalitis. Numbers and fractions of CNS in-
filtrating immune cells were comparable between groups
(data not shown) indicating that antigen specific priming
in the peripheral immune compartment and establish-
ment of inflammatory infiltrates within the CNS werenot impaired in Prf1-/- mice. Moreover, wild type mice
that were vaccinated with MVA and then depleted of
CD4+ T cells in addition to CD8+ T cells succumbed to
intrathecal challenge with VV although they had similar
fractions of NK cells and NK T cells in the CNS as
their CD4+ T cell replete counterparts (Additional file 3:
Figure S3) suggesting that alternative sources of Prf1
other than CD4+ T cells were insufficient to provide
protection in this model. Taken together, these data
demonstrated that Prf1 expression was indispensable
for effector T helper cell mediated control of intra-
thecal VV infection.
Discussion
In this study, we tested the concept that host defense
against viral infections of the CNS requires distinct T
helper cell subsets. We show that access inhibition to
the CNS of selected T helper cell subsets by integrin
targeted interventions results in the failure of host
defense. Intrathecal infection with vaccinia virus (VV)
was controlled in vaccinated mice when CD4+ and CD8+ T
cells had access to the CNS compartment. Blockade of
α4-integrins by neutralizing antibodies or T cell condi-
tional disruption of α4-integrin expression did not prevent
CTLs and Th17 cells from entering the CNS parenchyma
while Th1 cells were blocked from migrating into the
CNS. When CD8+ CTLs were depleted, host defense
against intrathecal VV infection was still maintained as
long as efficient Th1 like responses were operational
within the CNS. In contrast, Th17 cells alone failed to
rescue individuals from CNS infection despite a strong in-
flammatory response. Perforin-1 expression by T helper
cells was required for clearance of intrathecal VV infection
and Th17 cells failed to eliminate VV in the CNS due to
lack of Eomes dependent Prf1 expression.
Adaptive cellular immune responses are necessary for
the clearance of systemic VV infection. CD8+ T cells
recognize epitopes from early antigens of VV but robust
CD4+ T cell responses are also required for direct and
indirect antiviral effects [27-30]. Niche restricted or
organ specific infection may afford specific effector func-
tions. For example, VV skin infection is contained and
cleared by a temporally and spatially organized inter-
action of Ly6G+ innate immune cells and CD8+ CTLs
[22]. In the ovaries, clearance of VV correlates with the
number of effector memory CTLs that are present in the
ovaries of VV immunized mice before challenge with the
virus [31]. Here, we established an intrathecal infection
model with VV and used this system as an in vivo surro-
gate to correlate the access of distinct T helper cell sub-
sets with successful host defense. Intrathecal infection of
naive wild type C57BL/6 mice with VV was lethal be-
cause adaptive antiviral immune responses did not de-































































































































































































































































Figure 4 Antibody mediated blockade of integrin α4 prevents entry of Th1, but not Th17 cells or CD8+ T cells into the CNS. Wild type
mice were sham immunized (PBS/CFA) or immunized with MVA/CFA followed by intrathecal VV challenge on day 10 after immunization. Control
IgG or antibodies to integrin α4 (PS/2) were administered every other day starting one day prior to VV challenge. (A) Weight courses of VV
challenged animals (n = 5 per group). (B, C) On day 4 after infection, CNS infiltrating mononuclear cells were isolated and the absolute number of
CD4+ T helper cells and CD8+ CTLs as well as the cytokine phenotype of CD4+ T helper cells from the CNS were assessed based on intracellular staining
for IFN-γ and IL-17. (B; numbers indicate percentages of CD4+ T cells in each quadrant; representative out of 5 independent experiments. The absolute
numbers of T cells were compared by Student’s t test, n≥ 3).
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were recruited to the infected CNS. Active immunization
of mice with MVA in CFA prior to i.th. VV challenge
protected the animals from lethal encephalitis. Protec-
tion was independent of neutralizing antibodies. How-
ever, access of VV specific Th1 cells into the CNS
compartment was necessary and sufficient for host
protection.Migration of effector cells into the CNS is mediated by
chemokine receptors and integrins. Several cytolytic and
non-cytolytic viral infection models of the CNS were
used to investigate principles of immune cell recruit-
ment into the CNS. Depending on the viral agent,
immune cell recruitment into the CNS cleared the
pathogen or in addition, caused immunopathogenic tis-
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Figure 5 VV specific Th17 cells are relatively enriched in the CNS compartment of α4 CKO mice but do not control i.th. VV infection.
CD4 Cre- x Itga4flox/flox mice (controls, WT) and α4 CKO mice were immunized with MVA/CFA, depleted of CD8+ T cells, and challenged i.th. with
VV. (A) After intrathecal infection with VV, the clinical course was monitored and weight loss was calculated as percentage of initial body weight
(n = 5 per group). On day 5 after infection, mice of each group were sacrificed. (B) The efficacy of CD8+ T cell depletion was analyzed by flow
cytometry in CNS mononuclear cells (gate on CD3+CD19- cells). (C) The viral load in the CNS was measured by means of plaque assay. CNS
infiltrating CD4+ T cells (D) and absolute numbers of cytokine positive CD4+ T cells (E) were calculated by surface staining and intracellular
cytokine analysis (Student’s t test, n ≥ 4 per group, representative out of n≥ 4 independent experiments). (F) CD4+ T cells were isolated by flow
cytometric purification from the CNS compartment of MVA immunized wild type vs α4 CKO mice 5 days after i.th. VV challenge. The expression
profile of the indicated genes was determined by quantitative PCR analysis, n = 4.
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http://www.actaneurocomms.org/content/2/1/27important for immune cell recruitment into the CNS in
west nile or MHV and LCMV infection, respectively
[32-35]. Chemotaxis of immune cells must be comple-
mented by integrin mediated interaction with endothelialcells for the transmigration of immune cells across the
blood brain barrier [36]. Early work suggested that accu-
mulation of antigen specific T cells in the CNS compart-
ment of sindbis virus infected animals is mediated by
AB
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Figure 6 Adoptive transfer of antigen specific Th1 cells but not Th17 cells promotes survival after intrathecal virus infection. Naïve CD4+CD25-
CD44- T cells from OT-II Ova323-339 specific TCR transgenic mice were polarized under Th1 or Th17 conditions in vitro. On day four of
differentiation, activated T cells were transferred into Rag1-/- mice, which had been infected with a recombinant VV expressing ovalbumin (VV-Ova)
one day earlier. (A) Kaplan-Meier curves of survival (left) and statistical evaluation of time to death (right) are shown. Horizontal bars in the right plot
indicate mean survival time in days (ANOVA, n≥ 5 per group). (B) Mice were sacrificed on day 6 after transfer and absolute numbers of adoptively
transferred CD3+CD4+ T cells in spleens and CNS were assessed (means are indicated by horizontal bars, n = 3 per group).
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http://www.actaneurocomms.org/content/2/1/27engagement of LFA-1 but not VLA-4 [37]. Using gen-
etic tools, we have recently shown that distinct T helper
cell subsets use distinct integrins to access the CNS
compartment in autoimmune inflammation. The entry
of Th17 cells into the subarachnoid space most likely
requires CCR6 and LFA-1 but is independent of VLA-4
[4,38]. In fact, Th17 cells express low levels of α4-
integrins since TGF-β, which is required for Th17 cell
commitment [17,39,40], inhibits the expression of α4-
integrins [41]. Interestingly, antigen specific CD8+
CTLs also migrated into the CNS independently of α4-
integrins (both in α4-integrin antibody blockade and T
cell conditional genetic disruption of Itga4). This is
consistent with the observation that CD4+ T cell are
preferentially reduced in CSF of natalizumab treated
patients as compared with CD8+ T cells resulting in the
reversion of the CSF CD4+/CD8+ ratio [23]. Although
one report suggested that CD8+ T cell influx into the CNS
was prevented by a blocking antibody to α4-integrins in
an intracerebral corona virus infection model, it is unlikely
that the recruitment of antigen specific CTLs was assessed
by Ifergan et al. since their model did not allow for active
priming and activation of adaptive T cell responses in thesystemic lymphoid compartment prior to intracerebral
challenge [42]. In contrast to Th17 cells, VLA-4 expres-
sion is indispensable and non-redundant for the capacity
of antigen experienced Th1 cells to infiltrate into the
subarachnoid space and the CNS compartment. Here,
we provide evidence that MHC class II positive infected
phagocytic cells in the CNS need to be cleared by Th1
cells in order to rescue mice from lethal encephalitis.
Thus, MVA-immune T cell conditional α4 KO mice
succumbed to intrathecal VV challenge because they
failed to recruit Th1 cells into the CNS despite regular
Th17 cell accumulation.
Antigen specific CD4+ T cells communicated with
virus infected macrophages within the CNS parenchyma
and only eliminated the infected cells when they were
sufficient in perforin-1 expression. In ectromelia infec-
tion, a natural mouse pox infection, perforin-1 expres-
sion by CD4+ T cells is required to clear the pathogen,
and CD4+ T cell mediated killing of hematopoietic MHC
class II expressing infected target cells occurs in the
draining lymph nodes, the liver, and the spleen [28]. Dir-
ect cytotoxic effects of antigen specific CD4+ T cells
were also reported in systemic VV infection [43]. In our
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Figure 7 Th17 cells fail to control VV encephalitis due to lack of Prf1 expression. (A) CD3+CD4+ T cells were highly purified by FACS sorting
from the CNS of MVA/CFA immunized wild type or α4 CKO mice on day 4 after intrathecal infection. Fold change in relative expression of
the indicated genes in α4 deficient vs. wild type control CD4+ T cells (log scale, means + SD, n = 4). (B) Flow cytometrically purified naïve
CD3+CD4+CD44-Foxp3- T cells were stimulated without exogenous cytokines (Th0) or differentiated into Th1 cells (IL-12 + anti-IL-4), or Th17
cells (TGF-β + IL-6). Levels of Prf1 RNA expression were measured by quantitative RT-PCR (left in B, means + SD, Student’s t test, n = 4). Time
course of Prf1 protein expression was determined by Western Blot in Th0, Th1, and Th17 cells from day 3 to day 5 of culture (right in B). (C) RNA levels
of Eomes were measured in wild type and α4 integrin deficient T cells isolated from the CNS of VV infected mice (means + SD, n = 4). (D) Naïve T cells
were differentiated into Th17 cells in vitro and transduced retrovirally with a control vector (pMIG) or an Eomes GFP vector (pMIG Eomes). GFP+ cells
were purified by flow cytometry and RNA levels of Eomes and Prf1 were measured in control transduced Th17 cells vs Th17 cells that ectopically
expressed Eomes (means + SD, n = 4).
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Figure 8 Prf1-/- mice succumb to VV encephalitis. Wild type and Prf1-/- mice were immunized with MVA/CFA and continuously depleted of
CD8+ T cells after intrathecal VV challenge. Weight courses of infected animals (n = 5 per group).
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haved like perforin-1 deficient animals and succumbed
to infection because perforin-1 expressing Th1 cells did
not reach the CNS compartment in the absence of VLA-
4. Like in EAE, the cytokine phenotype of T helper cells
that entered into the CNS compartment in the absence
of α4-integrin showed a Th17 profile [4]. Th17 cells did
not express perforin-1. Initial Th17 cell commitment is
sensitive to IL-2 and high IL-2 concentrations inhibit
Th17 differentiation [44]. In contrast, IL-2 promotes the
expression of granzyme B and perforin-1 and boosts
cytotoxic capacity of CD4+ T cells [45]. While the tran-
scriptional control of granzyme B and perforin-1 has in
part been investigated in CD8+ T cells [46], we found
that perforin-1 expression in Th1 cells is associated with
Eomes and overexpression of Eomes in Th17 cells par-
tially reconstituted perforin-1 expression. Similar obser-
vations have been reported for Th2 cells that per se also
lack perforin-1 [26], which correlates with their low
cytotoxic efficacy. However, lack of perforin-1 expression
in Th17 cells may not be the only mechanism to impair
their antiviral capacity. For example, Th17 cells are able
to mount a protective response in primary lung infection
with influenza in IL-10 KO mice suggesting that Th17
cells are particularly susceptible to IL-10 mediated sup-
pression [47]. In addition, induction of prosurvival fac-
tors by Th17 cells may contribute to viral persistence in
the CNS in Theiler’s virus infection [48]. Conversely, it
is possible that in some anatomical niches, Th17 cells
may contribute to protective antiviral immune responses,
e.g. by effective IL-17 mediated recruitment of neutrophils
in lung infection [49]. Also, IL-21, which is produced by
Th17 cells, might have a role in the modulation of primary
and recall CTL responses by increasing their proliferation
and reducing their sensitivity to exhaustion [50]. However,
overall it is a more common scenario that antiviral Th17
responses fail to clear viral pathogens but rather drive
deleterious immunopathology in the skin [51], in the
cornea [52], and also in the CNS.
We have shown that blockade or genetic lack of α4-
integrins on T cells selectively modulated the access of T
helper cell subsets to the CNS. Preferential limitation of
Th1 trafficking jeopardized host defense against intrathecal
VV infection. Nevertheless, our experimental system has
several limitations: First, i.th. inoculation of VV does not
represent a natural route of CNS infection. Yet,
immunization with virus antigens in CFA provides an
efficient way to generate both an antigen specific Th1 and
Th17 response in the secondary lymphoid tissue and to
study their trafficking and effector functions upon i.th. chal-
lenge with a well characterized pathogen. Second, i.th. VV
infection results in an acute encephalomyelitis, which
causes rapid decay and death of infected animals; in con-
trast, JC virus induced PML is due to insufficient control ofa latent virus infection of oligodendrocytes. However, the
intracerebral anti-JC virus CD4+ T cell response contributes
substantially to JCV control because efficient clearance of
JC virus from the CNS after immune reconstitution by
wash-out of natalizumab in MS patients with PML is asso-
ciated with the re-occurrence of Th1 cells in the CNS [53].
Conclusions
Our experimental model provides a mechanistic explanation
for insufficient virus control under conditions of altered T
cell migration. Our data raise the concern that treatment of
humans with compounds like natalizumab that interfere
with T cell trafficking not only by quantitatively reducing the
migration of T cells into the CNS but also by selectively tar-
geting distinct T cell subsets may evoke serious deficiencies
in cellular immune responses at privileged anatomical sites
like the CNS. As a result, primary infections or unexpected
reactivations of latent viruses may be facilitated.
Supporting data
The data sets supporting the results of this article are
included within the article and its additional files.
Additional files
Additional file 1: Figure S1. α4 integrin deficiency in T cells does not
alter priming or humoral responses against VV after immunization. (A) CD4
Cre- x Itga4flox/flox mice (wild type control (WT)) or CD4 Cre+ x Itga4flox/flox
mice (α4 CKO) were immunized with MVA/CFA. On day 10 after
immunization, splenocytes were isolated and restimulated with an I-Ab
restricted peptide epitope mix of VV. Fractions of antigen specific cytokine
producing CD4+ T cells were determined by intracellular CD40L (CD154)
and cytokine staining. Numbers in the gates represent means ± SD, n = 3.
(B) Specific serum neutralization capacity of sera collected on day 10
after immunization of wild type or α4 CKO mice vaccinated with PBS/CFA
or MVA/CFA (specific neutralization capacity in percent of maximum,
means + SD, n = 5).
Additional file 2: Figure S2. IFN-γ expression in CD4+ T cells is not
required for virus control in the CNS. (A) Wild type mice were immunized
with MVA/CFA and challenged intrathecally with VV on day 10. Starting
one day before VV challenge, neutralizing antibodies to IFN-γ (or control
IgG) and depleting antibodies to CD8 were applied alternatingly every
other day. Weight courses of infected animals were measured every day
after infection and depicted relative to initial body weight (n = 5 per
group). (B) Expression of MHC class II on CNS microglial cells (gating on
CD11bintCD45int, upper panel) was measured on day 6 after infection
using surface staining and flow cytometric analysis. Numbers indicate
percentages. Histogram: black line: MHC class II expression on migroglia
from control IgG treated mice, grey/shaded line: MHC class II expression
on microglia from anti-IFN-γ treated mice. The numbers in the
histogram represent mean fluorescence intensities. Representative
out of 3 independent experiments.
Additional file 3: Figure S3. CD4+ T cells mediate protection against
VV encephalitis in the absence of CD8+ T cells. Wild type mice
immunized with MVA/CFA were challenged i.th. with VV and depleted of
CD8+ T cells. Concomitantly, animals were treated with isotype control or
depleting antibodies to CD4 every other day. (A) Percentage of surviving
mice are depicted in Kaplan-Meier curves of survival (n = 6 per group).
(B) CNS infiltrating mononuclear cells were analyzed by flow cytometry.
Upper panel: Staining for CD4 and CD8 in the CD3+ T cell gate. Lower
panel: Staining for CD3 and Nk1.1 in the CD4- gate (representative out of
4 independent experiments).
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